October 5, 2012
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Sarepta Therapeutics (Nasdaq: SRPT ) has received the dreaded one-star ranking.
With that in mind, let's take a closer look at Sarepta's business and see what CAPS investors are saying about the stock right now.
||Bothell, Wash. (1980)
||CEO Christian Garabedian
Principal Accounting Officer Michael Jacobsen
|Return on Equity (average, past 3 years)
||$24.5 million / $1.8 million
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 25% of the 249 members who have rated Sarepta believe the stock will underperform the S&P 500 going forward.
Just yesterday, one of those bears, All-Star pavlos1971, cautioned Fools about getting too excited over over Sarepta's Duchenne muscular dystrophy drug:
Congratulations to Sarepta (formerly AVI) for bringing a very promising technology one step closer to becoming a cure. My red thumb in CAPS marks what I believe is an exaggerated emotional reaction to a great result in the phase IIb trial. ... The importance of the fact that eteplirsen has shown no side effects thus far cannot be overstated, of course, but I still see a long path prior to regulatory approval. This is one of the few cases where I wish I am wrong in CAPS.
If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.